Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,087 recruiting studies in this area right now.
By phase
- Not applicable2,108
- Phase 21,118
- Phase 1824
- Phase 1/Phase 2483
- Phase 3349
- Phase 4127
- Phase 2/Phase 378
Top conditions
- Multiple Myeloma332
- Acute Myeloid Leukemia292
- Lymphoma182
- Sickle Cell Disease140
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia123
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Mantle Cell Lymphoma62
- Anemia60
- Diffuse Large B Cell Lymphoma57
- Lymphedema49
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center65
- City of Hope Medical Center61
- Mayo Clinic61
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California405
- Texas186
- Maryland149
- Alabama148
- Arizona124
- Florida111
- Massachusetts101
- New York98
- Ohio70
- Minnesota68
Recruiting studies5,087 total
- NCT05004233Recruiting
Antiplatelet treatment imaging test for stroke patients
This study uses special microscope imaging (transmission electron microscopy) to look at tiny changes in platelets before and after starting an antiplatelet medicine. It’s testing whether platelets show clear structural signs around the start of treatment for a specific type of stroke.
Saint-EtienneAges 18 years+ - NCT05003986RecruitingPhase 2
Sparsentan for children with protein leaking kidney diseases
This Phase 2 study tests sparsentan in children with certain kidney diseases that cause high amounts of protein in the urine. It aims to see if the medicine can reduce kidney damage signals and protein leakage compared with standard care.
Los Angeles, CaliforniaAges 1–17 - NCT05006482RecruitingPhase 3
Geriatric education and care support for older cancer survivors
This study tests whether a structured health education and “older adult care” approach—done with your oncology team—can improve support for people after cancer. It includes older cancer survivors and a chosen caregiver, using in-person or video visits for follow-up.
Tuscaloosa, AlabamaAges 18 years+ - NCT05010005RecruitingPhase 1
Testing ruxolitinib plus duvelisib for relapsed T-cell lymphoma
This Phase 1 study tests how safe and effective ruxolitinib plus duvelisib are in adults with certain types of mature T-cell lymphomas. You may be considered if your lymphoma has come back or worsened despite prior treatment, and the study checks whether this pill combination can help control the disease.
Miami, FloridaAges 18 years+ - NCT05010122RecruitingPhase 1/Phase 2
Testing venetoclax and gilteritinib with ASTX727 for FLT3 leukemia
This Phase 1/2 trial tests a combination of medicines (ASTX727, venetoclax, and gilteritinib) for adults with FLT3-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to see how well the treatment works and how safe it is for people whose disease has come back, is not responding, or (for some) is newly diagnosed.
Houston, TexasAges 18 years+ - NCT05010564RecruitingPhase 1
TRICAR-ALL CAR-T treatment for tough childhood leukemia
This Phase 1 trial tests a customized CAR-T cell therapy for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that keeps coming back or doesn’t respond to treatment. It aims to find a safer and effective way to control leukemia by targeting specific markers on the leukemia cells.
Houston, TexasAges 1–25 - NCT05010772RecruitingPhase 1
Maintenance treatment study for AML in remission
This Phase 1 trial tests whether continuing decitabine alone or with other targeted drugs can help prevent AML from coming back after you reach remission. It’s designed to study safety and how well these maintenance options work for people who are not immediately able to get a stem cell transplant.
Houston, TexasAges 18 years+ - NCT05011045Recruiting
Brain radiation study tracking thinking and memory changes
This study looks at how whole-brain radiation affects thinking, memory, and other brain function in people with blood cancers that involve the brain. It may help doctors understand what to expect and which supportive treatments or monitoring could be useful.
Houston, TexasAges 18 years+ - NCT05012111Recruiting
Study of bone marrow failure causes over time
This study looks at the natural history (how a condition progresses) in people with acquired or inherited bone marrow failure syndromes, including related lung and liver findings in some cases. It helps researchers understand underlying causes—sometimes linked to gene or telomere changes—and how symptoms evolve, which may guide future care.
Bethesda, MarylandAges 2–99 - NCT05014165Recruiting
Cord blood study for leukemia with stored birth samples
This study looks at leukemia “genetic clues” using special stored samples, including cord blood saved at birth. It may help researchers better understand leukemia biology and how common mutations may show up early.
Minneapolis, MinnesotaAges Up to 25 years - NCT05018520RecruitingPhase 3
Two chemotherapy schedules for newly diagnosed low-risk DLBCL
This trial compares two different shortened treatment schedules of R-CHOP to see which one is safer and works better for people with low-risk diffuse large B-cell lymphoma (DLBCL). It aims to reduce risk from treatment while maintaining strong cancer control after an initial response.
Shanghai, Shanghai MunicipalityAges 14–75 - NCT05022446Recruiting
Survey study on how COVID-19 affected lung procedures
This study is a survey sent to U.S. lung doctors to understand how COVID-19 changed the way certain lung procedures are done. Your answers could help improve future care and planning during respiratory outbreaks.
Houston, TexasAges Any age - NCT05023564Recruiting
Dementia care study following people with a steady caregiver
This study follows people diagnosed with dementia over time, with the help of a consistent caregiver, to better understand how dementia changes. It may help by adding new information that could improve future care and planning for families.
BeijingAges 18 years+ - NCT05025488RecruitingPhase 1
CALR-mutant blood cancer vaccine for adults with high-risk ET or PMF
This Phase 1 study tests a vaccine made from a CALR mutation (a specific genetic change) to help the immune system recognize and fight your blood cancer. It is mainly focused on early safety and to see if the vaccine can trigger an immune response in people with CALR-mutated myeloproliferative neoplasms.
New York, New YorkAges 18 years+ - NCT05025098RecruitingPhase 2
Targeted treatment versus standard care for older blood cancer patients
This Phase 2 trial compares a “precision” treatment plan with standard therapy for older adults with AML or MDS. It aims to improve outcomes while using treatments that may be better suited for people who cannot have intensive chemotherapy.
LørenskogAges 60 years+ - NCT05025774Recruiting
Exercise program study for young heart, leukemia, and lung survivors
This study looks at how an exercise program affects fitness and lung function in young people who are survivors of certain conditions (heart transplant, leukemia, or lung disease from prematurity). The goal is to see whether exercise can improve breathing and overall physical function safely.
Minneapolis, MinnesotaAges 8–25 - NCT05029531RecruitingPhase 3
Immuno-chemotherapy for infants with B-lineage ALL
This trial tests a combination of medicines (immunotherapy plus chemotherapy) in babies diagnosed with a type of leukemia called B-lineage acute lymphoblastic leukemia (ALL). It aims to improve how well treatment works and is delivered safely in very young children.
Moscow, Samory-Mashela,1Ages 1 day–12 months - NCT05031897RecruitingPhase 2
Haplo transplant with reduced donor mismatch and radiation
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
Philadephia, PennsylvaniaAges 18 years+ - NCT05037760RecruitingPhase 2
Elritercept alone or with ruxolitinib for myelofibrosis
This Phase 2 trial tests whether elritercept, given alone or together with ruxolitinib, can improve symptoms and disease control in adults with myelofibrosis. It may help people who have anemia and either cannot tolerate, can’t get enough benefit from, or are already using ruxolitinib.
Concord, New South WalesAges 18 years+ - NCT05038696RecruitingPhase 1
CAR T-cell treatment for hard-to-control B-ALL
This Phase 1 trial tests a personalized “CAR T” cell treatment for people with relapsed or treatment-resistant B-lymphoblastic leukemia (B-ALL). It may help the immune system find and kill leukemia cells, especially when leukemia has not responded to standard treatment.
SingaporeAges 6 months–80 years - NCT05040555Recruiting
Testing a new chemo plan for newly diagnosed high-burden lymphoma
This trial studies a specific treatment plan to see how well it works for adults with newly diagnosed non-Hodgkin lymphoma that has a high amount of disease. It may help by aiming to control lymphoma more effectively, especially when it is widespread.
Changchun, JilinAges 18–75 - NCT05043571RecruitingPhase 1
CAR T-cell therapy for relapsed T-cell leukemia
This early-phase trial tests a lab-made immune cell treatment (CAR T-cells) aimed at T-cell leukemia that has come back or did not respond. It may help by targeting leukemia cells with a specific marker (CD7), especially in patients who failed standard treatment.
SingaporeAges 6 months–65 years - NCT05046444Recruiting
Testing tricky blood cancer diagnoses with advanced DNA sequencing
This study uses advanced DNA sequencing to figure out unclear or unusual blood (hematologic) conditions when standard tests are not enough. It may help your care team reach a more accurate diagnosis by better understanding what’s driving your illness.
MunichAges 18–99 - NCT05053607Recruiting
Text and Fitbit monitoring during isatuximab treatment
This trial follows people with multiple myeloma who are getting isatuximab through a vein (IV). It tests how well real-world health tracking (text/app messages and Fitbit data) works during treatment, and whether it can help care teams understand your experience.
Houston, TexasAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,087 recruiting hematology studies from the U.S. registry right now, out of 7,715 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.